Key facts
- This page summarizes Stephen R. Brady's Form 4 filing for Tempest Therapeutics, Inc. (TPST).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jul 2024, 16:15.
Stephen R. Brady - 03 Jul 2024 Form 4 Insider Report for Tempest Therapeutics, Inc. (TPST)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- TPST
- Reported as of
- 03 Jul 2024
- Net transaction value
- +$73,850
- SEC form
- 4
- Accepted by SEC
- 08 Jul 2024, 16:15:11 UTC
- Prior SEC filing
- 05 Jan 2024
- Next SEC filing
- 06 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nicholas Maestas, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen R. Brady filed Form 4 for Tempest Therapeutics, Inc. (TPST) on 08 Jul 2024.
Change
- Previous filing in this sequence was filed on 05 Jan 2024.
- Current net transaction value: +$73,850.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TPST
transaction
Common Stock
Purchase
- Transaction value
- $73,850
- Shares
- +35,000
- Change %
- +308%
- Price
- $2.11
- Shares after
- 46,376
- Date
- 03 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Includes 11,376 shares acquired under the Issuer's stock purchase plan.